Spinraza

News

England to start screening newborns for rare disease SMA

All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.

News

FDA knocks back Biogen's high-dose Spinraza

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

News

Biogen buys CNS delivery specialist Alcyone Therapeutics

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Biogen races into phase 3 with Spinraza follow-up

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking a candidate offering once-yearly dosing into phase 3.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

News

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than

England to start screening newborns for rare disease SMA

FDA knocks back Biogen's high-dose Spinraza

Biogen buys CNS delivery specialist Alcyone Therapeutics

Biogen races into phase 3 with Spinraza follow-up

US/EU regulators start review of Biogen's high-dose Spinraza

Roche puts pressure on SMA rivals with new FDA approval

UK biotech venture investment remains buoyant in Q2

Discover a new era of healthcare panel engagement: Grounded ...

Spinraza

Editor's Picks